Skip to main content
OpenTrials

Clinical trial condition

Neoplasms by Site

Explore clinical trials studying Neoplasms by Site. Study availability and eligibility vary by location and protocol.

140 public trials 44 recruiting studies
Refine in advanced search Browse all conditions

Neoplasms by Site trial results

Recruiting

Ocular Assessments in Patients Treated With Tivdak® in Recurrent or Metastatic Cervical Cancer

NCT06952660

Conditions
Cervical Cancer, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, +11 more
Locations
  • HonorHealth Cancer Care - Biltmore - AZCCC Imaging Phoenix, Arizona, United States
  • HonorHealth Cancer Care - Biltmore - HonorHealth Research Pharmacy Phoenix, Arizona, United States
  • HonorHealth Research Institute (Arizona Center for Cancer Care) - HonorHealth Cancer Care -Biltmore Phoenix, Arizona, United States
  • Sonora Quest Laboratories, LLC Phoenix, Arizona, United States
View all 132 locations
View Trial Details
Recruiting

TheraSphere Japan Pre-Market Study

NCT07377487

Conditions
Adenocarcinoma, Carcinoma, Carcinoma, Hepatocellular, +24 more
Locations
  • Hyogo College of Medicine Hospital Nishinomiya, Hyōgo, Japan
  • Kanazawa University Hospital Kanazawa, Ishikawa-ken, Japan
  • Kindai University Hospital Sayama, Osaka, Japan
  • National Cancer Center Hospital Chuo Ku, Tokyo, Japan
View Trial Details
Recruiting

Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors

NCT06128551

Conditions
Adenocarcinoma, Adnexal Diseases, Appendiceal Neoplasms, +59 more
Locations
  • City of Hope Duarte, California, United States
  • UC IRVINE Health Orange, California, United States
  • UC Davis Comprehensive Cancer Center Sacramento, California, United States
  • Stanford Cancer Institute Stanford, California, United States
View all 56 locations
View Trial Details
Recruiting

(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis

NCT04996875

Conditions
Advanced Systemic Mastocytosis (AdvSM), Aggressive Systemic Mastocytosis (ASM), Bone Marrow Diseases, +35 more
Locations
  • University of Alabama at Birmingham (UAB) Hospital Birmingham, Alabama, United States
  • Mayo Clinic Arizona Phoenix, Arizona, United States
  • City of Hope Comprehensive Cancer Center Duarte, California, United States
  • UCLA Medical Center Los Angeles, California, United States
View all 42 locations
View Trial Details
Recruiting

Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy (cCRT) in People With Muscle Invasive Bladder Cancer (EV-309)

NCT07566156

Conditions
Carcinoma, Carcinoma, Transitional Cell, Female Urogenital Diseases, +13 more
Locations
  • Samsun Clinic - Ridley-Tree Cancer Center Santa Barbara, California, United States
  • Medical Oncology Hematology Consultants Newark, Delaware, United States
  • Illinois Cancer Specialists Niles, Illinois, United States
  • Fort Wayne Medical Oncology and Hematology Fort Wayne, Indiana, United States
View all 14 locations
View Trial Details
Recruiting

Safety, Pharmacokinetics, and Preliminary Efficacy of VIR-5500 (AMX-500) in Prostate Cancer

NCT05997615

Conditions
Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, +11 more
Locations
  • Investigational Site Number: 403 Palo Alto, California, United States
  • Investigational Site Number: 401 Houston, Texas, United States
  • Investigational Site number: 404 Fairfax, Virginia, United States
  • Investigational Site Number: 400 Seattle, Washington, United States
View all 13 locations
View Trial Details
Recruiting

Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer

NCT05386108

Conditions
Brain Diseases, Brain Neoplasms, Breast Diseases, +9 more
Locations
  • Providence Medical Foundation Fullerton, California, United States
  • California Research Institute Los Angeles, California, United States
  • Carle Cancer Center Urbana, Illinois, United States
  • Dana-Farber Cancer Institute Boston, Massachusetts, United States
View all 86 locations
View Trial Details
Recruiting

A Phase IIIb Study to Evaluate Camizestrant Plus Ribociclib in ER-positive, HER2-negative Advanced Breast Cancer

NCT07647328

Conditions
Breast Diseases, Breast Neoplasms, ER-Positive HER2-Negative Breast Cancer, +8 more
Locations
  • Research Site Duarte, California, United States
  • Research Site Palo Alto, California, United States
  • Research Site Marietta, Georgia, United States
  • Research Site Evanston, Illinois, United States
View all 89 locations
View Trial Details

Related conditions